2024-11-13 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance vs S&P 500**

Johnson & Johnson (JNJ) is a multinational healthcare company that develops, manufactures, and sells a wide range of pharmaceutical, medical device, and consumer products.  

JNJ's cumulative return is **57.49%**, significantly lagging behind the S&P 500 (VOO) which has a cumulative return of **179.25%**. This results in a **-121.76** points difference in the cumulative return. The relative divergence is **0.0** which suggests JNJ is currently at the lowest point in its historical performance compared to the S&P 500. 

**Alpha/Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 45.2% | 9.1% | 6.8% | 0.7 | 336.4 |
| 2016-2018  | 39.2% | 16.9% | 6.9% | 0.7 | 310.7 |
| 2017-2019  | 36.4% | 16.9% | -15.3% | 0.7 | 351.2 |
| 2018-2020  | 22.6% | 27.1% | -24.7% | 0.7 | 378.9 |
| 2019-2021  | 45.0% | 27.1% | -55.0% | 0.6 | 411.9 |
| 2020-2022  | 30.8% | 27.1% | 7.2% | 0.5 | 425.3 |
| 2021-2023  | 8.6% | 15.2% | -26.4% | 0.3 | 377.4 |
| 2022-2024  | -3.7% | 15.2% | -34.0% | 0.2 | 373.3 |

JNJ has consistently outperformed the S&P 500 with positive alpha values until 2018, demonstrating its ability to generate excess returns. However, since then, the alpha values have been consistently negative, indicating underperformance against the benchmark. JNJ's beta values have been steadily declining, indicating a decrease in the volatility of the stock relative to the market.

**2. Recent Price Movement**

* **Closing Price:** 152.64
* **5-day Moving Average:** 155.55
* **20-day Moving Average:** 160.36
* **60-day Moving Average:** 162.26

JNJ's current price is below all three moving averages, indicating a potential downward trend. 

**3. Technical Indicators**

* **RSI:** 9.84
* **PPO:** -0.52
* **Delta_Previous_Relative_Divergence:** -7.24

The RSI suggests the stock is in oversold territory, which could signal a potential rebound. However, the negative PPO and Delta_Previous_Relative_Divergence indicates a downward trend in the short term. The current price of 152.65 is not significantly high or low to suggest any extreme price movement.

**Expected Return:** 0.0% 

JNJ's expected return is currently 0%, suggesting that long-term investors who plan to hold JNJ for more than 2 years may not expect to see significant outperformance against the S&P 500. 

**4. Recent Earnings and Outlook**

| Date       | EPS | Revenue        |
|------------|-----|-----------------|
| 2024-10-23 | 1.12 | 22.47 B$       |
| 2024-07-25 | 1.95 | 22.45 B$       |
| 2024-05-01 | 1.35 | 21.38 B$       |
| 2024-02-16 | 1.68 | 21.39 B$       |
| 2023-10-27 | 10.32 | 21.35 B$       |

The most recent earnings report for the quarter ending 2024-09-30 is expected to be released soon. 

JNJ's revenue has been relatively stable over the last few quarters, but its earnings per share (EPS) have been fluctuating. 

**5. Financial Information**

**1) Revenue and Profitability**

| Quarter      | Revenue  | Profit Margin |
|--------------|---------|---------------|
| 2024-09-30 | $22.47B | 69.01%       |
| 2024-06-30 | $22.45B | 69.40%       |
| 2024-03-31 | $21.38B | 69.55%       |
| 2023-12-31 | $21.39B | 68.23%       |
| 2023-09-30 | $21.35B | 69.06%       |

JNJ has consistently maintained a high profit margin, indicating strong profitability. Its revenue has grown steadily, but slowed down in recent quarters.

**2) Capital and Profitability**

| Quarter      | Equity    | ROE |
|--------------|----------|-----|
| 2024-09-30 | $70.16B  | 3.84% |
| 2024-06-30 | $71.54B  | 6.55% |
| 2024-03-31 | $70.02B  | 4.65% |
| 2023-12-31 | $68.77B  | 5.89% |
| 2023-09-30 | $71.23B  | 36.54% |

JNJ's equity has been relatively stable, but the ROE has fluctuated significantly, indicating variations in the company's efficiency in generating profits from its shareholders' equity.

**6. News and Recent Issues**

**Analyst Opinions and Performance Highlights:**

* FINBOLD reports that JNJ has a "Strong Buy" rating from analysts with a target price of **$175.04**.
* JNJ has faced some recent headwinds due to a **lawsuit related to its talcum powder products**, leading to some investor concerns. 
* However, JNJ continues to **invest heavily in research and development**, particularly in areas like pharmaceuticals and medical devices, which could potentially drive future growth.

**7. Overall Analysis**

Johnson & Johnson (JNJ) is a large and diversified healthcare company with a strong track record of profitability. Despite lagging behind the S&P 500 in recent years, JNJ's strong financial performance and continued investment in innovation suggest it could potentially bounce back in the future. However, investors should carefully consider the recent legal issues surrounding its talcum powder products before making an investment decision. While the stock is currently oversold and may offer a potential entry point for long-term investors, its future performance remains uncertain.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. You should consult with a financial professional before making any investment decisions.